LAM
ACAD icon

Lebenthal Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Lebenthal Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-800
Closed -$25K – 321
2016
Q3 		$25K Buy
+800
New +$27.1K ﹤0.01% 557

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lebenthal Asset Management's ACAD Position: Q4 2016 in Review

Lebenthal Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2016, closing a stake of 800 shares — an estimated $25K sold.

Lebenthal Asset Management first reported a position in ACAD in Q3 2016 and held it in 1 quarter. The position peaked at $25K in Q3 2016. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • Lebenthal Asset Management reported no remaining Acadia Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Lebenthal Asset Management sold 800 Acadia Pharmaceuticals shares in Q4 2016, an estimated $25K.
  • Lebenthal Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Lebenthal Asset Management's Acadia Pharmaceuticals position peaked at $25K in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on Lebenthal Asset Management's 13F filing for Q4 2016, filed 15 Feb 2017.